(1)

The Withdrawal Agreement (2) sets out the arrangements for the withdrawal of the United Kingdom of Great Britain and Northern Ireland (‘United Kingdom’) from the Union and from the European Atomic Energy Community.

(2)

The transition period set out in Part Four of the Withdrawal Agreement ends on 31 December 2020 when the Union law ceases to apply to and in the United Kingdom.

(3)

Pursuant to Article 5(4) of the Protocol on Ireland/Northern Ireland to the Withdrawal Agreement, read in conjunction with Annex 2 to that Protocol, the provisions of Regulation (EU) 2019/125 will apply to and in the United Kingdom in respect of Northern Ireland as from the end of the transition period.

(4)

Where Regulation (EU) 2019/125 establishes an authorisation requirement for trade from the Union to third countries, it would be the ‘competent authority’ of the United Kingdom which, from 1 January 2021will be responsible for deciding on any applications for such an authorisation pursuant to that Regulation made by exporters established or residing in Northern Ireland.

(5)

Subject to the application of Regulation (EU) 2019/125 to and in the United Kingdom in respect of Northern Ireland, in accordance with Article 5(4), of the Protocol on Ireland/Northern Ireland to the Withdrawal Agreement, read in conjunction with point 47 of Annex 2 to that Protocol, it is therefore appropriate to amend Annex I to Regulation (EU) 2019/125.

(6)

Pursuant to Articles 16 and 19 of Regulation (EU) 2019/125, an authorisation is required for exporting products listed in Annex IV to the Regulation which could be used for the execution of human beings by means of lethal injection.

(7)

Article 20(1) of Regulation (EU) 2019/125 provides for a ‘Union general export authorisation’.

(8)

In accordance with Annex V to Regulation (EU) 2019/125, the Union general export authorisation applies to exports of goods listed in any entry in Annex IV to Regulation (EU) 2019/125 and is valid throughout the Union for exports to the destinations listed in Part 2 of Annex V. Those destinations are third countries that have abolished capital punishment for all crimes and confirmed that abolition through an international commitment (3).

(9)

The Union general export authorisation helps minimise the regulatory burden placed on Union companies exporting goods listed in Annex IV to the Regulation when exporting such medicinal products for legitimate therapeutic purposes.

(10)

The United Kingdom ratified Protocol No 13 to the Convention for the Protection of Human Rights and Fundamental Freedoms concerning the abolition of the death penalty in all circumstances and therefore meets the requirements for inclusion in the list of destinations laid down in Annex V Part 2 to Regulation (EU) 2019/125.

(11)

Without prejudice to the application of Regulation (EU) 2019/125 to and in the United Kingdom in respect of Northern Ireland, in accordance with Article 5(4), read in conjunction with Annex 2, point 47, of the Protocol on Ireland/Northern Ireland annexed to the Withdrawal Agreement, it is therefore appropriate to amend Annex V to Regulation (EU) 2019/125.

(12)

It is appropriate to provide for the applicability of this Regulation after the end of the transition period, with effect from 1 January 2021. If the objection period ends later than 1 January 2021, it is appropriate for reasons of legal certainty and to avoid any potential detrimental disruption to the operations of Union companies wanting to export goods listed in Annex IV to the United Kingdom to provide for a retroactive applicability of the Regulation from 1 January 2021,